Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL).
Wayne Su
Consultant or Advisory Role - Teva
Peter Quon
Consultant or Advisory Role - Teva
John Whalen
Consultant or Advisory Role - Teva
Research Funding - Teva
Gayatri Ranganathan
Consultant or Advisory Role - Teva
Samantha Wronski
Consultant or Advisory Role - Teva
Mkaya Mwamburi
Consultant or Advisory Role - United Biosource Corporation
Kevin B. Knopf
Consultant or Advisory Role - United Biosource Corporation
James A. Sterchele
Employment or Leadership Position - Teva
Christopher G. Salvador
Employment or Leadership Position - Teva
Ipek Ozer Stillman
Consultant or Advisory Role - Teva
Ananth Kadambi
Consultant or Advisory Role - Teva